Charles E. Miller

ORCID: 0000-0002-1892-2818 · 18 papers in corpus · active 1997-2025

Study types

  • article 14
  • review 2
  • letter 1
  • rct 1

Condition tags

  • endometriosis 11
  • mesh:D004715 7
  • infertility 2
  • mesh:D017699 2
  • mesh:D004412 2
  • mesh:D004414 2
  • adenomyosis 2
  • dysmenorrhea 1
  • dyspareunia 1
  • endometrioma 1
article 2025
How to bridge the gap between evidence-based and clinical management of endometriosis
·doi:10.1016/j.jeud.2025.100123

• The limitations of EBM and guidelines to take dichotomous decisions, based on multiple variables, are discussed for endometriosis management. • It is suggested to document for clinical decisions on diagnosis, treatment and surgery the col…

article 2025
Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain
AJOG global reports ·doi:10.1016/j.xagr.2025.100584

Background: Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss of bone mi…

article 2025
The Evidence-Based Medicine Management of Endometriosis Should Be Updated for the Limitations of Trial Evidence, the Multivariability of Decisions, Collective Experience, Heuristics, and Bayesian Thinking
Journal of clinical medicine ·doi:10.3390/jcm14010248

Background/Objectives: The diagnosis and treatment of endometriosis should be based on the best available evidence. Emphasising the risk of bias, the pyramid of evidence has the double-blind, randomised controlled trial and its meta-analyse…

rct 2024
Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2024.06.040

BACKGROUND: Elagolix, an approved oral treatment for endometriosis-associated pain, has been associated with hypoestrogenic effects when used as monotherapy. Hormonal add-back therapy has the potential to mitigate these effects. OBJECTIVE:…

article 2024
LONG-TERM ELAGOLIX + ADD-BACK THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN FOR 48 MONTHS + 12 MONTH POST-TREATMENT FOLLOW-UP: A SAFETY UPDATE ON BONE MINERAL DENSITY DATA OF A PHASE 3 STUDY
·doi:10.1016/j.fertnstert.2024.07.557
article 2023
PREGNANCY AND LIVE BIRTH OUTCOMES IN PATIENTS WITH SECONDARY INFERTILITY UNDERGOING LAPAROSCOPIC ISTHMOCELE REPAIR: A RETROSPECTIVE STUDY OF A PROSPECTIVELY MAINTAINED DATABASE
·doi:10.1016/j.fertnstert.2023.08.528
article 2021
AAGL 2021 Endometriosis Classification: An Anatomy-based Surgical Complexity Score
Journal of minimally invasive gynecology ·doi:10.1016/j.jmig.2021.09.709
letter 2021
Author's Reply
·doi:10.1016/j.jmig.2021.11.021
review 2020
The Endometrioma Treatment Paradigm when Fertility Is Desired: A Systematic Review
Journal of minimally invasive gynecology ·doi:10.1016/j.jmig.2020.11.020
article 2019
Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women
The Journal of clinical endocrinology and metabolism ·doi:10.1210/clinem/dgz086

CONTEXT: Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist recently approved for the treatment of endometriosis-associated pain and being developed for heavy menstrual bleeding associated with uterine fibroids. OBJECTIVE:…

article 2015
Change in Pain and Quality of Life Among Women Enrolled in a Trial Examining the Use of Narrow Band Imaging During Laparoscopic Surgery for Suspected Endometriosis
Journal of minimally invasive gynecology ·doi:10.1016/j.jmig.2015.06.017
article 2014
Persistent Bleeding After Laparoscopic Supracervical Hysterectomy
JSLS : Journal of the Society of Laparoendoscopic Surgeons ·doi:10.4293/jsls.2014.002064

BACKGROUND AND OBJECTIVES: In our clinical experience, there seemed to be a correlation between cervical stump bleeding and adenomyosis. Therefore, we wanted to conduct a study to determine whether there was an actual correlation and to ide…

article 2013
Is There a Correlation of Adenomyosis with Cervical Stump Bleeding after a Laparoscopic Supracervical Hysterectomy?
·doi:10.1016/j.jmig.2013.08.037
article 2013
Pregnancy Outcomes for Women with Endometriosis Undergoing IVF with Luteal Phase Support via a Progesterone Vaginal Insert or Progesterone Vaginal Gel
·doi:10.1016/j.fertnstert.2013.01.029
article 2011
The Singer, Not the Song
Journal of minimally invasive gynecology ·doi:10.1016/j.jmig.2011.06.016
review 2007
Laparoscopic ureteral injury and repair: case reviews and clinical update
Journal of Minimally Invasive Gynecology ·doi:10.1016/j.jmig.2006.10.023

Ureteral injuries are known complications of pelvic surgery. The incidence is 0.5% to 3%, and approximately one-third of these cases are not identified or corrected intraoperatively. It is critical to recognize and repair these injuries int…

article 2006
Endoscopic Treatment for Infertility
·doi:10.1016/j.cpen.2006.08.002
article 1997
Laparoscopic assisted vaginal hysterectomy of the large uterus using ultrasonic dissection.
Surgical technology international

Laparoscopic assisted vaginal hysterectomy (LAVH) is a procedure gaining in popularity over abdominal hysterectomy, for a number of different indications. According to a recent study by Wilcox, et al., over 1.7 million women underwent a hys…